Keele spin-out completes seed funding round

Funding round completed

Keele University spin-out nanoTherics has secured seed funding from The Mercia Technology Seed Fund, a regional venture capital fund. The size of the investment was not disclosed.

The company is developing a drug delivery system based on nanoparticles and magnetic fields for delivering molecules including DNA, into living cells. The aim is to develop the technology for gene therapy.

nanoTherics’ gene transfection studies have shown a significant performance improvement over the best non-viral methods of delivering DNA currently on the market. The company says the technology provides high levels of transfection while, importantly, maintaining the viability of the transfected cells.

nanoTherics’s aims to position its gene transfection technology as the new gold standard for transfection, underpinning the research and development of current and future gene therapy programmes.

Neil Farrow, chief operating officer of nanoTherics, said, “We are delighted to be working alongside the Mercia Technology Seed Fund, a fund highly experienced in growing early stage technology companies such as nanoTherics.”